Michael Laffan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6352051/publications.pdf

Version: 2024-02-01

83 papers	4,527 citations	196777 29 h-index	120465 65 g-index
85 all docs	85 docs citations	85 times ranked	7743 citing authors

#	Article	IF	Citations
1	Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UKâ€‰â€”â€‰a multicentre observational study. British Journal of Haematology, 2022, 196, 79-94.	1.2	8
2	Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 445-448.	0.9	3
3	Impact of major bleeding and thrombosis on 180â€day survival in patients with severe COVIDâ€19 supported with venoâ€venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. British Journal of Haematology, 2022, 196, 566-576.	1.2	27
4	Practical treatment guidance for cancer-associated thrombosis â€“ Managing the challenging patient: A consensus statement. Critical Reviews in Oncology/Hematology, 2022, 171, 103599.	2.0	6
5	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Advances, 2022, 6, 121-128.	2.5	7
6	Complement activation during cardiopulmonary bypass and association with clinical outcomes. EJHaem, 2022, 3, 86-96.	0.4	2
7	Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. New England Journal of Medicine, 2022, 386, 1013-1025.	13.9	157
8	Outcomes of longâ€term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia, 2022, 28, 373-387.	1.0	5
9	Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom. Rheumatology, 2022, 61, 4643-4655.	0.9	4
10	Thrombophilia testing: A British Society for Haematology guideline. British Journal of Haematology, 2022, 198, 443-458.	1.2	29
11	von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis. Haemophilia, 2021, 27, 66-74.	1.0	17
12	The heparinâ€von Willebrand factor interaction and conventional tests of haemostasis â€“ the challenges in predicting bleeding in cardiopulmonary bypass. British Journal of Haematology, 2021, 192, 1073-1081.	1.2	8
13	Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVIDâ€19 while we are awaiting the results of clinical trials?. British Journal of Haematology, 2021, 192, 459-466.	1.2	17
14	Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2021, 47, 436-441.	1.5	9
15	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	2.5	152
16	The clinical course of COVIDâ€19 in pregnant versus nonâ€pregnant women requiring hospitalisation: results from the multicentre UK CAâ€COVIDâ€19 study. British Journal of Haematology, 2021, 195, 85-89.	1.2	6
17	Survey evaluating clinical equipoise around platelet transfusion after head injury and traumatic intracranial haemorrhage (ICH) in patients on antiplatelet medications. Emergency Medicine Journal, 2021, , emermed-2021-211189.	0.4	1
18	Impact of Thrombosis and Bleeding in Patients with Severe COVID-19 versus Other Viral Pneumonias in the Context of Extracorporeal Membrane Oxygenation. Seminars in Thrombosis and Hemostasis, 2021, , .	1.5	7

#	Article	IF	Citations
19	Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia, 2021, 27, 947-956.	1.0	62
20	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial. Blood, 2021, 138, 3972-3972.	0.6	0
21	Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. New England Journal of Medicine, 2020, 382, 29-40.	13.9	316
22	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
23	A Mendelian randomization of Î³â€² and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke. Blood, 2020, 136, 3062-3069.	0.6	25
24	Thrombolysis restores perfusion in COVIDâ€19 hypoxia. British Journal of Haematology, 2020, 190, e270-e274.	1.2	29
25	Practical guidance for the management of adults with immune thrombocytopenia during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 189, 1038-1043.	1.2	89
26	Red cell alloimmunisation in patients receiving veno-venous extracorporeal membrane oxygenation (VV-ECMO). Intensive Care Medicine, 2020, 46, 1932-1933.	3.9	2
27	Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. British Journal of Haematology, 2020, 191, 347-362.	1.2	32
28	Frequency of Thrombocytopenia and Heparin-Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation Compared With Cardiopulmonary Bypass and the Limited Sensitivity of Pretest Probability Score. Critical Care Medicine, 2020, 48, e371-e379.	0.4	17
29	Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVIDâ€19. British Journal of Haematology, 2020, 190, e286-e288.	1.2	37
30	Effect of directâ€acting oral anticoagulants (DOACs) on bleeding and blood product usage in cardiac surgery compared to warfarin and controls. British Journal of Haematology, 2020, 190, 284-293.	1.2	0
31	Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47â€“58): use of direct acting oral anticoagulants. British Journal of Haematology, 2020, 189, 212-215.	1.2	53
32	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 2020, 18, 1233-1234.	1.9	192
33	Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHESS US Dataset. Blood, 2020, 136, 25-26.	0.6	2
34	Prospective Study Reveals Increased Platelet Function Associated with Multiple Myeloma and Its Treatment. Blood, 2020, 136, 21-21.	0.6	0
35	Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms. Seminars in Thrombosis and Hemostasis, 2019, 45, 604-611.	1.5	39
36	Limitations on point care APTT for monitoring of unfractionated heparin in intensive care patients. Thrombosis Research, 2019, 181, 124-126.	0.8	2

#	Article	IF	Citations
37	Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders. A UK Haemophilia Centre Doctorsâ€™ Organisation Good Practice Paper. Haemophilia, 2019, 25, 116-126.	1.0	17
38	NICE NG89 recommendations for extended pharmacological thromboprophylaxis â€“ is it justified and is it cost effective: a rebuttal from the British Society for Haematology. British Journal of Haematology, 2019, 186, 790-791.	1.2	6
39	Utility of fibrinogen in the coagulation screen. British Journal of Haematology, 2019, 186, e137-e139.	1.2	1
40	The top 10 research priorities in bleeding disorders: a James Lind Alliance Priority Setting Partnership. British Journal of Haematology, 2019, 186, e98-e100.	1.2	8
41	The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood, 2019, 133, 2559-2569.	0.6	81
42	Intracranial Hemorrhage and Early Mortality in Patients Receiving Extracorporeal Membrane Oxygenation for Severe Respiratory Failure. Seminars in Thrombosis and Hemostasis, 2018, 44, 276-286.	1.5	46
43	Quality assurance and tests of platelet function. British Journal of Haematology, 2018, 181, 560-561.	1.2	3
44	Thrombophilia in nonâ€thrombotic chronic venous disease of the lower limb â€“ a systematic review. British Journal of Haematology, 2018, 183, 703-716.	1.2	1
45	The use of viscoelastic haemostatic assays in the management of major bleeding. British Journal of Haematology, 2018, 182, 789-806.	1.2	160
46	Incidence of Thrombocytopenia and Heparin Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Compared to Cardiopulmonary Bypass and the Limited Sensitivity of Pre-Test Probability Score. Blood, 2018, 132, 2451-2451.	0.6	1
47	Congenital Aspirin-like Defect As a Result of Autosomal Recessive Variants in PTGS1. Blood, 2018, 132, 1156-1156.	0.6	0
48	Efficacy and Safety of Prothrombin Complex Concentrate in Patients Treated with Rivaroxaban or Apixaban Compared to Warfarin Presenting with Major Bleeding. Blood, 2018, 132, 2535-2535.	0.6	2
49	The Relationship between Thrombin Generation Assay and FVIII Levels in Patients with Mild to Moderate Haemophilia (A). Blood, 2018, 132, 2454-2454.	0.6	0
50	Pathogenesis and management of antiphospholipid syndrome. British Journal of Haematology, 2017, 178, 181-195.	1.2	80
51	Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature, 2017, 541, 81-86.	13.7	743
52	Should we abandon the APTT for monitoring unfractionated heparin?. Thrombosis Research, 2017, 157, 157-161.	0.8	48
53	AAV5â€“Factor VIII Gene Transfer in Severe Hemophilia A. New England Journal of Medicine, 2017, 377, 2519-2530.	13.9	529
54	Can you grow out of von Willebrand disease?. Haemophilia, 2017, 23, 807-809.	1.0	7

#	Article	IF	Citations
55	Thromboelastography (TEGÂ®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section. International Journal of Obstetric Anesthesia, 2017, 29, 50-56.	0.2	5
56	S109â€…Adamts13 protein levels are decreased in chronic thromboembolic pulmonary hypertension and implicated in its pathobiology. , 2017, , .		0
57	Inherited platelet disorders: toward DNA-based diagnosis. Blood, 2016, 127, 2814-2823.	0.6	119
58	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood, 2016, 128, 1959-1968.	0.6	31
59	New products for the treatment of haemophilia. British Journal of Haematology, 2016, 172, 23-31.	1.2	18
60	International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. Journal of Thrombosis and Haemostasis, 2016, 14, 3-27.	1.9	12
61	Ein genomweiter Ansatz bei Thrombozyten-und GerinnungsstÃ¶rungen. Hamostaseologie, 2016, 36, 161-166.	0.9	4
62	Patients with Splanchnic Vein Thrombosis Demonstrate Significantly Increased Platelet Activity. Blood, 2016, 128, 1430-1430.	0.6	0
63	Differential Expression of Genes Associated with Oncogene-Induced Senescence and Senescence Associated Secretory Phenotype in the Absence of Differential Expression of High Molecular Risk Genes and Genes Associated with JAK-STAT Pathway in Sorted Cells of Patients with Polycythemia Vera and Primary Myelofibrosis. Blood, 2016, 128, 4283-4283.	0.6	0
64	Guideline on aspects of cancerâ€related venous thrombosis. British Journal of Haematology, 2015, 170, 640-648.	1.2	139
65	Safety and pharmacokinetics of antiâ€TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. Journal of Thrombosis and Haemostasis, 2015, 13, 743-754.	1.9	195
66	Gene Expression Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Polycythemia Vera and Primary Myelofibrosis. Blood, 2015, 126, 5201-5201.	0.6	0
67	Transcriptional diversity during lineage commitment of human blood progenitors. Science, 2014, 345, 1251033.	6.0	253
68	Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. International Journal of Laboratory Hematology, 2013, 35, 1-13.	0.7	131
69	Guidelines on the investigation and management of venous thrombosis at unusual sites. British Journal of Haematology, 2012, 159, 28-38.	1.2	119
70	PhaseÂI, randomized, doubleâ€blind, placeboâ€controlled, singleâ€dose escalation study of the recombinant factorÂVIIa variant BAYÂ86â€6150 in hemophilia. Journal of Thrombosis and Haemostasis, 2012, 10, 773-780.	1.9	36
71	Blocking von Willebrand factor: a novel anti-platelet therapy. Journal of Thrombosis and Haemostasis, 2009, 7, 1152-1154.	1.9	1
72	Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort.. Blood, 2008, 112, 2275-2275.	0.6	0

#	Article	IF	Citations
73	The South East England Thrombotic Thrombocytopenic Purpura Registry.. Blood, 2006, 108, 1064-1064.	0.6	0
74	Soil erodibility and erosion hazard: Extending these cornerstone soil conservation concepts to headwater streams in the forestry estate in Tasmania. Forest Ecology and Management, 2005, 220, 128-139.	1.4	18
75	The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia, 2004, 10, 199-217.	1.0	164
76	Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagulation and Fibrinolysis, 2003, 14, S35-S38.	0.5	50
77	Site assessment for farm forestry in Australia and its relationship to scale, productivity and sustainability. Forest Ecology and Management, 2002, 171, 133-152.	1.4	16
78	Genetic and Phenotypic Variability between Families with Hereditary Protein S Deficiency. Thrombosis and Haemostasis, 2002, 87, 258-265.	1.8	32
79	A Tyr346â†'Cys substitution in the interdomain acidic regiona1of factor VIII in an individual with factor VIII:C assay discrepancy. British Journal of Haematology, 2002, 118, 589-594.	1.2	46
80	rHuEpo TREATMENT IN LOW-RISK MYELODYSPLASTIC SYNDROMES. British Journal of Haematology, 1999, 106, 573-574.	1.2	0
81	Genetics and pulmonary medicine bullet Â4: Pulmonary embolism. Thorax, 1998, 53, 698-702.	2.7	8
82	Rearrangement of T-cell Receptor (Delta, Gamma and Beta) Genes and its Significance in T-cell Chronic Leukaemias. Leukemia and Lymphoma, 1991, 4, 17-25.	0.6	0
83	Impact of aspirin on bleeding and blood product usage in offâ€pump and onâ€pump coronary artery bypass graft surgery. EJHaem, 0, , .	0.4	0